GERN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

50.88M

+7.03%

-0.032

-20.83%

53.85M

+35.97%

-0.032

+6.67%

60.07M

+22.51%

-0.018

-10%

Estimates Revision

The market is revising Downward the revenue expectations for Geron Corporation (GERN) for FY2025, with the revenue forecasts being adjusted by -8.78% over the past three months. During the same period, the stock price has changed by 2.29%.

Revenue Estimates for FY2025

Revise Downward

-8.78%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.25%

In Past 3 Month

Stock Price

Go Up

+2.29%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast GERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GERN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

Goldman Sachs

initiated

2025-07-10

Reason

Goldman Sachs

Price Target

2025-07-10

initiated

Reason

Goldman Sachs resumed coverage of Geron with a Sell rating and $1 price target, which suggests 31% downside. The initial launch of the company's lead product and first commercial drug, Rytelo, has disappointed, and the near-term trajectory for the launch will be modest, the analyst tells investors in a research note.

Scotiabank

Greg Harrison

Outperform -> Sector Perform

downgrade

$1.50

2025-05-08

Reason

Scotiabank

Greg Harrison

Price Target

$1.50

2025-05-08

downgrade

Outperform -> Sector Perform

Reason

Scotiabank analyst Greg Harrison downgraded Geron to Sector Perform from Outperform with a $1.50 price target.

Scotiabank

Greg Harrison

Outperform -> Sector Perform

downgrade

2025-05-08

Reason

Scotiabank

Greg Harrison

Price Target

2025-05-08

downgrade

Outperform -> Sector Perform

Reason

As previously reported, Scotiabank analyst Greg Harrison downgraded Geron to Sector Perform from Outperform with a price target of $1.50, down from $4. As the company manages a slowdown in its launch of Rytelo in MDS, the firm emphasized that its rating change "is not solely due to the miss on the quarter," which had an inventory drawdown, but it sees the weak result as further evidence of the challenges that lie ahead and is concerned about the flattening of the launch less than a year in, necessitating a revised commercial strategy.

Wedbush

Outperform -> NULL

downgrade

$7 -> $6

2025-05-08

Reason

Wedbush

Price Target

$7 -> $6

2025-05-08

downgrade

Outperform -> NULL

Reason

Wedbush lowered the firm's price target on Geron to $6 from $7 and keeps an Outperform rating on the shares following quarterly results. Based on the firm's discussion with management, Wedbush believes both a lack of awareness of Rytelo overall, and an apparent wariness of cytopenias associated with Rytelo treatment are key issues for uptake - the firm sees these issues as fixable with recent HCP education efforts.

HC Wainwright & Co.

Emily Bodnar

Hold

Reiterates

n/a

2025-03-12

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

n/a

2025-03-12

Reiterates

Hold

Reason

Needham

Gil Blum

Strong Buy

Reiterates

2025-03-12

Reason

Needham

Gil Blum

Price Target

2025-03-12

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Geron Corp (GERN.O) is -14.39, compared to its 5-year average forward P/E of -9.19. For a more detailed relative valuation and DCF analysis to assess Geron Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.19

Current PE

-14.39

Overvalued PE

-2.34

Undervalued PE

-16.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.51

Current EV/EBITDA

-5.14

Overvalued EV/EBITDA

17.09

Undervalued EV/EBITDA

-26.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1113.45

Current PS

3.63

Overvalued PS

2579.76

Undervalued PS

-352.85

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 226.92% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GERN News & Events

Events Timeline

No data

News

5.0

2025-12-18Newsfilter

Geron Corporation Grants 320,000 Stock Options to New Employee

3.0

2025-12-18Benzinga

Investor Claims He 'Doubled' His Savings by Utilizing ChatGPT for Stock Research – Reveals His Top 5 Stock Picks

4.5

2025-12-18Yahoo Finance

Geron Corporation (GERN) Restructures to Reduce Operating Costs in Pursuit of Profitability by 2026

People Also Watch

Frequently Asked Questions

What is Geron Corp (GERN) stock price today?

The current price of GERN is 1.34 USD — it has decreased -2.19 % in the last trading day.

What is Geron Corp (GERN)'s business?

Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.

What is the price predicton of GERN Stock?

What is Geron Corp (GERN)'s revenue for the last quarter?

Geron Corp revenue for the last quarter amounts to 47.23M USD, increased 67.05 % YoY.

What is Geron Corp (GERN)'s earnings per share (EPS) for the last quarter?

Geron Corp. EPS for the last quarter amounts to -0.03 USD, decreased -25.00 % YoY.

What changes have occurred in the market's expectations for Geron Corp (GERN)'s fundamentals?

How many employees does Geron Corp (GERN). have?

Geron Corp (GERN) has 229 emplpoyees as of January 10 2026.

What is Geron Corp (GERN) market cap?

Today GERN has the market capitalization of 855.40M USD.